Gastric Diffuse Adenocarcinoma
NCI Definition: An adenocarcinoma arising from the stomach. Microscopically, it is characterized by the presence of a diffuse infiltrate, composed of individual adenocarcinoma cells or groups of adenocarcinoma cells in a fibrous or mucoid stroma. Many cells contain mucin droplets, producing a signet-ring configuration. 
Gastric diffuse adenocarcinomas most frequently harbor alterations in TP53, CDH1, ARID1A, CDKN2A, and KRAS .
TP53 Mutation, TP53 c.217-c.1178 Missense, TP53 Missense, CDH1 Mutation, and TP53 Exon 7 Mutation are the most common alterations in gastric diffuse adenocarcinoma .
There is 1 clinical trial for gastric diffuse adenocarcinoma, of which 1 is open and 0 are completed or closed. Of the trial that contains gastric diffuse adenocarcinoma as an inclusion criterion, 1 is phase 2 (1 open).
Crizotinib is the most common intervention in gastric diffuse adenocarcinoma clinical trials.
Significant Genes in Gastric Diffuse Adenocarcinoma
ERBB2 is altered in 4.72% of gastric diffuse adenocarcinoma patients .
ERBB2 is an inclusion eligibility criterion in 1 clinical trial for gastric diffuse adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and gastric diffuse adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.